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Abstract. The major role of liver glycogen is to supply glucose 
to the circulation in order to maintain normal blood glucose 
levels. in the muscle and liver, the accumulation and break-
down of glycogen are regulated by the reciprocal activities 
of glycogen phosphorylase and glycogen synthase. Glycogen 
phosphorylase catalyses the key step of glycogen degradation 
and its activity is inhibited by glucose and its analogues. Thus, 
any readily accessible inhibitor of glycogen phosphorylase 
may serve as a potential therapy for non-insulin-dependent 
or type 2 diabetes. Hepatic glycogen phosphorylase has been 
identified as a novel target for drugs that control blood glucose 
concentration. Glucopyranosylidene-spiro-thiohydantoin (TH) 
was found to be one of the most potent glucose derivates, inhib-
iting the catalytic activity of both muscle and liver glycogen 
phosphorylase. Here, we demonstrated the co-ordinated regu-
lation of glycogen phosphorylase and synthase by 50 µM TH 
in liver extracts of Wistar rats, resulting in the activation of 
synthase by a shortening of the latency compared to control 
animals. TH was also effective in lowering blood glucose 
levels and restoring hepatic glycogen content in streptozotocin-
induced diabetic rats. Furthermore, intravenous administration 
of TH to Zucker diabetic fatty rats significantly decreased 
hepatic glycogen phosphorylase a levels, and the activation of 
synthase was initiated without any delay. 
Introduction
Type 2 diabetes (non-insulin-dependent diabetes mellitus) is a 
major public health problem with severe complications, such 
as cardiovascular disease, neuropathy, retinopathy and neph-
ropathy. Type 2 diabetes comprises approximately 90-95% of 
all diabetes cases (1). diabetes affects approximately 6-20% 
of the adult population in Western industrialized societies 
(2) and is a major public health threat, reaching epidemic 
rates (2,3). The disease is polygenic and is characterized by 
hyperglycemia, defects in insulin secretion and insulin resis-
tance, in which the tissues fail to respond to this hormone (4). 
additionally, the rate of endogenous glucose production is 
elevated in type 2 diabetes (5). 
The liver accounts for 90% of the body's endogenous 
glucose production and is tightly controlled by insulin and 
glucagon. in type 2 diabetes, hepatic insulin resistance with 
elevated amounts of glucagon results in high levels of glucose, 
which in turn contributes to the observed hyperglycemia (6). 
Hepatic glucose is produced via two pathways: glycogenolysis 
(breakdown of glycogen) and gluconeogenesis (de novo 
synthesis of glucose). Studies estimate the glycogenolytic 
contribution of total hepatic glucose production to be up to 
75% in both healthy controls (7) and patients with type 2 
diabetes (8). Furthermore, a substantial portion of glucose 
formed by gluconeogenesis is cycled through the glycogen 
pool prior to efflux from the liver cells (9). The inhibition 
of either glycogenolysis or gluconeogenesis appears to be an 
attractive approach to developing antihyperglycemic mole-
cules. Glycogen phosphorylase (GP), which catalyzes the first 
reaction in the degradation of glycogen, is considered a poten-
tial target for type 2 diabetes, generating selective ligands of 
GP that modulate the activity of this protein (10-15).
The accumulation and breakdown of glycogen are regu-
lated by the reciprocal activities of glycogen synthase (GS) 
and GP. only the phosphorylated GPa has significant activity, 
suggesting an important role for glycogenolysis in hepatic 
glucose production. Therefore, the inhibition of hepatic GP 
might suppress glucose production arising from glycogenol-
ysis and gluconeogenesis (16,17). it is known that the activity 
of liver GS is also controlled by reversible phosphorylation of 
multiple serine residues. The dephosphorylated form of GS is 
the catalytically active (GSa) form. Phosphorylation is associ-
ated with the inactivation of GS: conversion to the b form. The 
dephosphorylation of GP and GS is interrelated and is cata-
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lyzed by the glycogen-associated protein phosphatase-1. GPa, 
but not GPb, is a potent inhibitor of the phosphatase action 
on GS, and it is only when GPa has been dephosphorylated 
that the phosphatase is free to activate GS, the rate limiting 
enzyme of glycogen synthesis (2,18,19).
rodents are commonly used for diabetic studies. 
Streptozotocin, a monofunctional nitrosourea derivative, is one 
of the most frequently applied substances to induce diabetes 
in experimental animals (20). Genetic models of insulin resis-
tance and hyperglycemia are also available, including zucker 
diabetic fatty (zdF) rats. These rats have a mutation in the 
leptin receptor and a defect in the pancreatic β cells that affect 
insulin production (21). 
There are several binding sites in GP that lend themselves 
to targeting by various effectors. Many glucose derivatives 
were shown to bind to the catalytic centre of GP (13,22), and 
among them glucopyranosylidene-spiro-hydantoin with a Ki 
of 3-4 µM was one of the most efficient inhibitors (23). More 
recent efforts resulted in the synthesis of a thio-analogue 
of the molecule with a very similar Ki value (24-26). in the 
present study, we report the effect of d-glucopyranosylidene-
spiro-thiohydantoin (TH) on glycogen metabolism in the liver 
tissues of streptozotocin-induced and obese diabetic rats. 
Materials and methods
Materials. TH was prepared from d-glucose in a six-step 
highly chemo-, regio- and stereoselective procedure (24-26). 
[γ-32P]ATP (specific activity of 15 TBq/mmol) was obtained 
from izinta (budapest, Hungary), and udP-[14c]-glucose was 
purchased from american radiolabeled chemicals (St. louis, 
Mo, uSa). Sephadex G-25 columns (1.5x5 cm) were supplied 
by Pharmacia (Uppsala, Sweden) and ET 31 filter paper by 
Whatman (clifton, nJ, uSa). other reagents of analytical 
grade from various suppliers were used for the preparation of 
buffers. 
Animals. Male Wistar rats weighing ~250 g were obtained 
from charles river Magyarország Kft. (budapest, Hungary). 
diabetes was induced by a simple intravenous injection of a 
freshly prepared solution of streptozotocin (60 mg/kg body 
weight) dissolved in 50 mM sodium citrate (pH 4.5) plus 
150 mM nacl. control rats were injected with citrate buffer 
alone. diabetes was assessed periodically by a test for gluco-
suria (Macherey-nagel, düren, Germany). one week after 
diabetes induction, the animals were determined to be diabetic 
if urine glucose levels exceeded 3 mg/ml. The diabetic animals 
were randomly divided into two groups: control diabetic 
and TH-treated diabetic. The control and the streptozotocin-
injected group were subcutaneously administered 0.9% nacl 
(2 ml/kg body weight) and the TH-treated streptozotocin-
injected group was subcutaneously administered 50 µM TH 
solution (100 µmol/kg body weight). TH was freshly dissolved 
in 0.9% nacl solution (50 µmol/ml). The treatments were 
performed 10 times between 8 and 9 a.m. every second day. 
rats were anesthetized on the second day after the 10th treat-
ment, the livers were removed by median laporotomy, and the 
wet liver weight was measured. zdF/Gmi-fa/fa (zdF) inbred 
obese male rats from Genetic Models, inc. (indianapolis, in, 
uSa) were ordered from charles river Magyarország Kft. 
all animals were cared for observing standard proce-
dures with permission of the laboratory animals Protection 
committee (29/2007/de Máb).
Gel filtered liver extract. The liver samples were immediately 
homogenized in a Potter-elvehjem tube in two-volume ice-cold 
buffer consisting of 250 mM sucrose and 40 mM Tris-Hcl 
(pH 7.4), and centrifuged at 10,000 x g for 10 min. The 
resulting post-mitochondrial supernatant was filtered through 
a Sephadex G-25 column (5x1.5 cm) to remove endogenous 
effectors, equilibrated in 40 mM Tris-Hcl, 1 mM edTa and 
10 mM mercapto-ethanol (pH 7.4). The filtrates were supple-
mented with 5 mM (nH4)2So4 and 1 mM magnesium acetate 
in the presence of various effectors and incubated at 30˚C. 
Samples were withdrawn at the indicated times for the assay 
of GP or GS (27).
Assays. GP activity was assayed in the direction of glycogen 
synthesis at 30˚C with 10 µg/ml enzyme and 1% glycogen in 
the absence of aMP (liver GPa) or in the presence of 2 mM 
aMP (liver GPb) in 50 mM triethanolamine/Hcl (pH 6.8) 
buffer, 100 mM Kcl, 1 mM dithiothreitol and 1 mM edTa. 
Hepatic GS was assayed according to dopere et al in the 
absence or presence of 10 mM glucose-6-phosphate (28). one 
unit of GP or GS converts 1 µmol substrate into product per 
min at 30˚C. Protein was assayed as described by Bradford 
(29) and glycogen was measured using the phenol sulphuric 
acid assay (30). Glucose was determined by an enzymatic 
assay (reanal, Hungary).
Results
Effect of TH on hepatic glycogen metabolism. it is known that 
glucose and glucose analogues cause a sequential inactivation 
(dephosphorylation) of liver GPa and activation (dephospho-
rylation) of GSb (31). The coordinated regulation of GP and 
GS was tested in gel-filtered rat liver extract. Fig. 1 illustrates 
the effect of 20 mM glucose and 50 µM TH on the dephos-
phorylation of GPa in gel-filtered rat liver extract catalysed 
by phosphorylase phosphatase. both ligands enhanced the 
dephosphorylation (inactivation) of hepatic GPa; however, TH 
applied at a much lower concentration appeared to be more 
effective. Fig. 1 also illustrates the effect of either glucose or 
TH on the dephosphorylation (activation) of GS in gel-filtered 
rat liver extract. TH significantly increased the active form of 
GS in the liver by decreasing the latency in the dephosphory-
lation of GS.
Effect of TH on hepatic glycogen metabolism of streptozotocin-
induced rats. Streptozotocin is widely utilized to induce type 1 
diabetes in rats with concomitant insulin deficiency (32), which 
is considered to be one of the animal models of human diabetes 
mellitus. one week after the injection of streptozotocin, the 
average blood glucose levels were >30 mmol/l in the diabetic 
group, and remained at this level during the experimental period 
of 4 weeks (Fig. 2a). Hepatic glycogen content dramatically 
decreased in the diabetic animals from 24 to 2 mg/g in the 
liver. diabetic animals treated with 100 µmol/kg body weight 
of TH exhibited significantly lower serum glucose levels, and 
the hepatic glycogen was also restored.
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The co-ordinated control of GP and GS in gel-filtered 
liver extracts in the three experimental groups is depicted 
in Fig. 2b. The diabetic group showed higher GPa activity 
compared to the control animals, while GS activity was mark-
edly suppressed in the streptozotocin-treated rats. TH-treated 
diabetic rats had the lowest GPa activity; however, GS activity 
was rather high, supporting the fact that glycogen concentra-
tion was elevated in the liver of this group.
Effect of TH on hepatic glycogen metabolism of Zucker diabetic 
fatty rats. The zdF rat develops overt diabetes with severe 
hyperglycemia, polyurea and polydipsia. Therefore, it is a good 
type 2 diabetic model for testing small molecule anti diabetic 
compounds. as shown in Fig. 3, the co-ordinated control of GP 
and GS was observed in the gel-filtered extracts of spontane-
ously diabetic rats. When the GPa level was lowered, GS was 
sequentially dephosphorylated, and through this the activation 
of glycogen synthesis was initiated. intravenous administration 
of TH significantly decreased the GPa level and the activation 
of GS was initiated without any delay.
Discussion
Liver GP has been identified as a novel target for drugs that 
control blood glucose concentration. Several compounds with 
different chemical structures have been probed for the inhi-
bition of hepatic GP. Glucose and its analogues were shown 
to be inhibitors of the enzyme. TH was found to be a potent 
glucose derivative that inhibits the catalytic activity of both 
muscle and liver GP enzymes (24,25). by means of a synthetic 
procedure using stereoselective preparation, it is possible to 
produce gram quantities of TH in six-to-seven steps starting 
from d-glucose (25,26). The structure of the GPb-TH complex 
as revealed by X-ray studies demonstrates that the inhibitor 
can be accomodated in the catalytic site of T-state GPb with 
very little change in the tertiary structure, and provides a basis 
for understanding the potency and specificity of TH (33). 
Figure 1. effect of TH on the dephosphorylation of GPa and GSb in gel-
filtered liver extract of male Wistar rats. Post-mitochondrial supernatants 
were prepared and filtered through a Sephadex G-25 column, as described 
in Materials and methods. The filtrates were supplemented with 5 mM 
(nH4)2So4 and 1 mM magnesium acetate (○,●) in the presence of 20 mM 
glucose (◻,◼) or 50 µM TH (△,▲), and incubated at 30˚C. Samples were with-
drawn at the indicated times for the assay of GPa or GS. The results are the 
mean ± Sd of four independent experiments.
Figure 2. Serum glucose, hepatic glycogen, GP and GS levels in streptozotocin-
induced diabetic rats treated with TH. (a) inactivation of GP (empty symbols) 
and activation of GS (filled symbols) in gel-filtered liver extracts. Post-
mitochondrial supernatants were prepared and filtered through a Sephadex G-25 
column, as described in Materials and methods. The filtrates were incubated at 
30˚C and samples were withdrawn at the indicated times for the assay of GPa or 
GS. control (○,●), diabetic control (◻,◼) and TH-treated diabetic rats (△,▲). (b) 
Effect of TH treatment on the concentration of blood glucose (filled column) 
and liver glycogen (hatched column) in streptozotocin-induced diabetic rats. 
The results are the mean ± Sd of four independent experiments.
  A
  B
Figure 3. effect of intravenously injected TH on the inactivation of GPa and 
activation of GSb in gel-filtered rat liver extract of spontaneously diabetic 
zucker rats. liver samples were removed from different liver lobules 
and post-mitochondrial supernatants were prepared and filtered through a 
Sephadex G-25 column, as described in Materials and methods. control 
biopsy (○,●); after the intravenous injection of TH (100 µmol/kg body 
weight) to the portal vein at 5 min (◻,◼). The results are the mean ± Sd of 
four independent experiments.
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Glucose and its analogues cause a sequential inactivation 
of GPa and activation (dephosphorylation) of GSb in the liver. 
We examined the co-ordinated regulation of GP and GS in 
rat liver extract and observed that 50 µM TH promoted the 
activation of GS by significantly decreasing the latency in 
the dephosphorylation of GS. The decrease of GPa activity, 
the increase of phosphatase activity and the increase of GS 
activity all result in the same biological response: the inhibi-
tion of hepatic glycogen breakdown, which in turn decreases 
the concentration of blood glucose. The mechanism by which 
TH inactivates GPa and activates GS may be complex and 
requires further study. However, the observed effects of TH 
clearly indicate that this compound and its analogues may be 
of potential use in controlling hyperglycaemia.
It is known that streptozotocin-induced diabetes influ-
ences glycogen metabolism in animal models. diabetic 
rats showed an approximately 4-fold higher blood glucose 
concentration and approximately 3-fold decrease in liver 
glycogen concentration compared to control or insulin-
treated diabetic animals (34). Similar results are depicted in 
Fig. 2. Furthermore, TH treatment restored these values to 
physiological ranges. our results suggest that the adminis-
tration of TH improves hyperglycemia, while inhibiting the 
breakdown and activating the synthesis of glycogen. The 
zdF rats also responded to the TH treatment; the active 
form of GP was decreased, which in turn triggered the 
synthesis of glycogen by activating GS (Fig. 3). Fr258900, 
a GP inhibitor isolated from the cultured broth of a fungal 
strain, also exhibited hypoglycaemic effects in diabetic 
animal models. FR258900 treatment significantly reduced 
plasma glucose concentrations during oral glucose tolerance 
tests in diabetic mice models, including db/db mice and 
streptozotocin-induced diabetic mice (35). 
it would appear that specific inhibition of hepatic GP 
results in a rapid decrease in plasma glucose levels in diabetic 
animals. These improvements in glucose disposal are accom-
panied by increased liver glycogen contents, suggesting that 
the glucose-lowering effect was the result of suppressed 
hepatic glycogen breakdown and increased hepatic glycogen 
synthesis. Taken together, our results suggest that GP is a 
potentially useful target in novel therapies against diabetes. 
The design and development of further glucose analogues 
for GP as potential therapeutic targets for diabetes have been 
comprehensively reviewed (13,14,22,36). These compounds 
primarily bind to the active site of GP, characterized by a 
d-glucopyranose ring having either diverse substituents 
or spirocyclic moieties attached to the anomeric carbon. 
exhaustive survey of non-glucose-type inhibitors targeting 
binding sites of GP other than the catalytic site has been 
conducted (13,14,37). The latest findings from physiological 
studies on novel GP inhibitors have been summarized by 
agius (15).
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